Tuesday, June 23, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 669 of 1,261
  1. US 9474728

    Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine

    TONIX PHARMA LIMITED · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  2. US 9474730

    Methods and compositions for use with K-ras mediated disorders

    The Board of Regents of the University of Texas System · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  3. US 9476052

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  4. US 9476051

    Antisense modulation of superoxide dismutase 1, soluble expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  5. US 9476037

    Factor VII polypeptides that are modified and uses thereof

    Catalyst Biosciences, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  6. US 9475880

    Anti-CD134 (OX40) antibodies and uses thereof

    Biocerox Products B.V. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  7. US 9475875

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  8. US 9475871

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  9. US 9476047

    RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  10. US 9475822

    Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors

    Takeda Pharmaceutical Company Limited · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  11. US 9475862

    Neutralizing GP41 antibodies and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  12. US 9475839

    Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  13. US 9468208

    Disease control with tick phospholipase A2

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  14. US 9469879

    Lymphoma prognostic methods and kits

    Regents of the University of Minnesota · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  15. US 9469878

    Methods of treating cancer comprising targeting NQO1

    The Board of Regents of the University of Texas System · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  16. US 9469683

    Lysosomal targeting peptides and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  17. US 9469664

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  18. US 9469637

    Nitrogenated heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  19. US 9468684

    Hydrogel implants with varying degrees of crosslinking

    Covidien LP · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  20. US 9468669

    Methods to treat dysregulated blood glucose disorders

    Regents of the University of Minnesota · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  21. US 9468611

    d-Methadone for the treatment of psychiatric symptoms

    Relmada Therapeutics, Inc. · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  22. US 9468624

    Small molecule antagonists of bacterial quorum-sensing receptors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  23. PT 2481410

    NITROCATECHOL DERIVATES AS COMT INHIBITORS ADMINISTERED WITH A SPECIFIC DOSAGE REGIME

    BIAL-PORTELA & Cª S A [PT] · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted
  24. US 9470689

    N-cadherin: target for cancer diagnosis and therapy

    The Regents of the University of California · Granted Oct 18, 2016 · Expires Oct 13, 2036

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.